Michael D. Allen

Array ( [id] => 16842910 [patent_doc_number] => 11014984 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-25 [patent_title] => Anti-CD47 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/999578 [patent_app_country] => US [patent_app_date] => 2020-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 8 [patent_no_of_words] => 19207 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 133 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16999578 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16621582 [patent_doc_number] => 20210040235 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => Multispecific Antibodies [patent_app_type] => utility [patent_app_number] => 16/996534 [patent_app_country] => US [patent_app_date] => 2020-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10432 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16996534 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16506234 [patent_doc_number] => 20200385490 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => Multispecific Antibodies [patent_app_type] => utility [patent_app_number] => 16/996510 [patent_app_country] => US [patent_app_date] => 2020-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9791 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 510 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16996510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16482520 [patent_doc_number] => 20200376120 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB [patent_app_type] => utility [patent_app_number] => 16/994950 [patent_app_country] => US [patent_app_date] => 2020-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41461 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16994950 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16581517 [patent_doc_number] => 20210015919 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB [patent_app_type] => utility [patent_app_number] => 16/992966 [patent_app_country] => US [patent_app_date] => 2020-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41446 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16992966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16613708 [patent_doc_number] => 20210032361 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING MAGE-A [patent_app_type] => utility [patent_app_number] => 16/943779 [patent_app_country] => US [patent_app_date] => 2020-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53855 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16943779 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17807487 [patent_doc_number] => 20220259322 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => ANTI-GRP78 ANTIBODIES AND METHOD OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/627502 [patent_app_country] => US [patent_app_date] => 2020-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17134 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17627502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17830159 [patent_doc_number] => 20220267463 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS [patent_app_type] => utility [patent_app_number] => 17/625719 [patent_app_country] => US [patent_app_date] => 2020-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64017 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -95 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17625719 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18020638 [patent_doc_number] => 20220372137 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/622499 [patent_app_country] => US [patent_app_date] => 2020-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21398 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17622499 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16398799 [patent_doc_number] => 20200339657 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS [patent_app_type] => utility [patent_app_number] => 16/916217 [patent_app_country] => US [patent_app_date] => 2020-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37627 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 144 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16916217 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17058952 [patent_doc_number] => 11103534 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-31 [patent_title] => Peptides and combination thereof for use in the immunotherapy against cancers [patent_app_type] => utility [patent_app_number] => 16/916220 [patent_app_country] => US [patent_app_date] => 2020-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 29 [patent_no_of_words] => 37807 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16916220 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16398798 [patent_doc_number] => 20200339656 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS [patent_app_type] => utility [patent_app_number] => 16/915797 [patent_app_country] => US [patent_app_date] => 2020-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37981 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 156 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16915797 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18323647 [patent_doc_number] => 20230121775 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => CD3 ANTIGEN BINDING FRAGMENTS AND COMPOSITIONS COMPRISING SAME [patent_app_type] => utility [patent_app_number] => 17/621993 [patent_app_country] => US [patent_app_date] => 2020-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69307 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17621993 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17297902 [patent_doc_number] => 20210393741 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => RECOMBINANT POLYPEPTIDES AND METHODS FOR USE IN THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/907820 [patent_app_country] => US [patent_app_date] => 2020-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49968 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16907820 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17982632 [patent_doc_number] => 20220348668 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => ANTI-CD123 ANTIBODIES, ANTI-CD123 CHIMERIC ANTIGEN RECEPTORS AND ANTI-CD123 CHIMERIC ANTIGEN RECEPTORS T CELLS [patent_app_type] => utility [patent_app_number] => 17/621504 [patent_app_country] => US [patent_app_date] => 2020-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30790 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 798 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17621504 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16598067 [patent_doc_number] => 20210024598 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => NOVEL RECOMBINANT BI-FUNCTIONAL FUSION PROTEIN AND PREPARATION AND APPLICATION THEREFOR [patent_app_type] => utility [patent_app_number] => 16/905262 [patent_app_country] => US [patent_app_date] => 2020-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8829 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16905262 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19969699 [patent_doc_number] => 12338291 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-24 [patent_title] => Humanized antibody molecules to CD138 and uses thereof [patent_app_type] => utility [patent_app_number] => 16/904090 [patent_app_country] => US [patent_app_date] => 2020-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 36 [patent_no_of_words] => 72611 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16904090 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17761523 [patent_doc_number] => 20220235135 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => ACTIVATING ANTI-GAL9 BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 17/614704 [patent_app_country] => US [patent_app_date] => 2020-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28890 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17614704 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16824292 [patent_doc_number] => 20210139585 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-13 [patent_title] => CD19 BINDING MOLECULES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/877878 [patent_app_country] => US [patent_app_date] => 2020-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 148307 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -186 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16877878 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19472617 [patent_doc_number] => 12102680 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-01 [patent_title] => Anti-TIGIT antibodies [patent_app_type] => utility [patent_app_number] => 16/806658 [patent_app_country] => US [patent_app_date] => 2020-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 25 [patent_no_of_words] => 62018 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16806658 [rel_patent_id] =>[rel_patent_doc_number] =>)